Loading
Loading
Organ & Bioregulator Research · 20mg
Janoshik-tested · 10 vials per kit
Cardiogen is a synthetic tetrapeptide bioregulator studied in preclinical research for its cardiovascular effects. Research has examined its potential to stimulate fibroblast proliferation, promote collagen and elastin synthesis, and inhibit cardiomyocyte apoptosis. Studies have explored potential applications in cardiac remodelling, hypertension, heart failure, coronary heart disease, myocarditis, and myocardial dystrophy models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Cardiogen
Cardiogen is a synthetic tetrapeptide developed as a cardiac bioregulator in the Khavinson series, targeting cardiomyocytes and cardiac endothelium. It is studied for regulatory effects on myocardial cell renewal and cardiovascular function in aged and compromised cardiac tissue.
Proposed mechanism involves binding to chromatin regulatory sequences in cardiac and vascular endothelial cells, influencing transcription of genes related to cardiomyocyte survival, antioxidant defence, and extracellular matrix remodelling. Anti-apoptotic effects in cardiomyocyte models exposed to hypoxia have been described in vitro.
Research in the Russian biogerontology literature includes myocardial infarction recovery models, age-related cardiac decline, and combination protocols with other organ bioregulators. Cardiogen is among the more studied Khavinson cardiac peptides with both in vitro and animal in vivo data published.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
